Last reviewed · How we verify

Analogous GnRH antagonist — Competitive Intelligence Brief

Analogous GnRH antagonist (Analogous GnRH antagonist) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: GnRH antagonist. Area: Oncology; Reproductive/Endocrinology.

phase 2 GnRH antagonist GnRH receptor (GnRHR) Oncology; Reproductive/Endocrinology Small molecule Live · refreshed every 30 min

Target snapshot

Analogous GnRH antagonist (Analogous GnRH antagonist) — Merck KGaA, Darmstadt, Germany. This GnRH antagonist blocks gonadotropin-releasing hormone receptors to suppress luteinizing hormone and follicle-stimulating hormone, reducing sex hormone production.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Analogous GnRH antagonist TARGET Analogous GnRH antagonist Merck KGaA, Darmstadt, Germany phase 2 GnRH antagonist GnRH receptor (GnRHR)
Cetrorelix and Leuprolide Cetrorelix and Leuprolide Instituto Valenciano de Infertilidad, IVI VALENCIA marketed GnRH antagonist and GnRH agonist combination GnRH receptor
Long acting FSH and GnRH antagonist Long acting FSH and GnRH antagonist Bioroma marketed GnRH antagonist / FSH receptor agonist combination GnRH receptor, FSH receptor
Antagon ™ Antagon ™ EMD Serono marketed GnRH antagonist GnRH receptor
Antagonist GnRH Cetrotide Antagonist GnRH Cetrotide Instituto Valenciano de Infertilidad, IVI VALENCIA marketed GnRH antagonist GnRH receptor
Degarelix (LHRH antagonist) Degarelix (LHRH antagonist) Rabin Medical Center marketed GnRH antagonist GnRH receptor
cetrorelix (cetrotide) cetrorelix (cetrotide) Eugonia marketed GnRH antagonist GnRH receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (GnRH antagonist class)

  1. Jiangsu HengRui Medicine Co., Ltd. · 2 drugs in this class
  2. Instituto Valenciano de Infertilidad, IVI VALENCIA · 2 drugs in this class
  3. AEterna Zentaris · 2 drugs in this class
  4. El Shatby University Hospital for Obstetrics and Gynecology · 1 drug in this class
  5. Eugonia · 1 drug in this class
  6. Instituto de Investigacion Sanitaria La Fe · 1 drug in this class
  7. Merck KGaA, Darmstadt, Germany · 1 drug in this class
  8. Rabin Medical Center · 1 drug in this class
  9. Sumitomo Pharma Switzerland GmbH · 1 drug in this class
  10. University of Edinburgh · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Analogous GnRH antagonist — Competitive Intelligence Brief. https://druglandscape.com/ci/analogous-gnrh-antagonist. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: